The short version
- Why people research itFat oxidation, appetite and energy regulation, insulin sensitivity and endurance capacity.
- What the evidence isFDA-approved as Trulicity for type 2 diabetes on the AWARD trial program, showing HbA1c reduction with modest weight loss.
- What to watchConstant upper belly pain boring through to the back, which can mean pancreatic inflammation.
How Dulaglutide works
In a catalog full of duals and triples, dulaglutide is the single-receptor control: GLP-1 receptor only, no GIP, no glucagon, no amylin. What makes it worth a deep page is not the receptor, which is the best-characterized target in metabolic medicine.
What the molecule is. Two GLP-1 analog chains, joined by a peptide linker to a modified human IgG4 Fc fragment — a covalent fusion protein of roughly 63 kDa. Every other weekly agent in this cohort is a small peptide with a fatty acid hung off it that borrows albumin as a carrier Muller 2022.
- Injectable
Can you get Dulaglutide?
Branded Trulicity only — no compounded or partner route exists.
Research on Dulaglutide5 evidence notes: clinical, correlative, mechanism
Each note is labeled by the kind of evidence it stands on. Unproven is not ineffective: a missing trial means nobody has run it yet. How the evidence tiers work
Human clinical evidence
FDA-approved as Trulicity for type 2 diabetes on the AWARD trial program, showing HbA1c reduction with modest weight loss.
REWIND (9,901 patients, 5.4 years) is the standout: it reduced major adverse cardiovascular events, and unusually most participants did not have established cardiovascular disease at entry — making it the strongest primary-prevention evidence in the class.
Correlative data
Widely prescribed, and reported as one of the better-tolerated agonists. Weight loss is real but smaller than semaglutide or tirzepatide, which is why it is rarely the choice when weight is the goal.
How the mechanism reads
GLP-1 fused to a modified IgG4 Fc fragment, which gives it a half-life of around five days by recycling through the neonatal Fc receptor — a completely different persistence strategy from liraglutide's albumin binding.
MechanisticThe large molecular size limits CNS penetration, which is a plausible explanation for why its appetite effect is weaker than semaglutide's despite comparable glycemic control. Size is the trade-off for duration here.
Mechanistic
Sources
- Gerstein HC, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet 2019 · PMID 31189511
- Frias JP, et al. Diabetes Care 2021 · PMID 33397768
- Bonora E, et al. Diabetes, Obesity and Metabolism 2021 · PMID 34189841
- Bajaj HS, et al. Erectile function in men with type 2 diabetes treated with dulaglutide: an exploratory analysis of the REWIND placebo-controlled randomised trial. Lancet Diabetes and Endocrinology 2021 · PMID 34153269
- Raubenheimer PJ, et al. Dulaglutide and incident atrial fibrillation or flutter in patients with type 2 diabetes: A post hoc analysis from the REWIND randomized trial. Diabetes, Obesity and Metabolism 2022 · PMID 34984808
- Sattar N, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes and Endocrinology 2021 · PMID 34425083
- He L, et al. Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases: A Systematic Review and Meta-analysis of Randomized Clinical Trials. JAMA Internal Medicine 2022 · PMID 35344001
- He Y, et al. Efficacy and safety of cAMP-biased GLP-1 receptor agonist ecnoglutide versus dulaglutide in patients with type 2 diabetes and elevated glucose concentrations on metformin monotherapy (EECOH-2): a 52-week, multicentre, open-label, non-inferiority, randomised, phase 3 trial. Lancet Diabetes and Endocrinology 2025 · PMID 40854315
- Zhang B, et al. Efficacy and Safety of Mazdutide in Chinese Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial. Diabetes Care 2023 · PMID 37943529
- Guo W, et al. Discovery of ecnoglutide - a novel, long-acting, cAMP-biased glucagon-like peptide-1 (GLP-1) analog. Molecular Metabolism 2023 · PMID 37364710
- Muller TD, et al. Anti-obesity drug discovery: advances and challenges. Nature Reviews Drug Discovery 2022 · PMID 34815532
- Stefanakis K, et al. The impact of weight loss on fat-free mass, muscle, bone and hematopoiesis health: Implications for emerging pharmacotherapies aiming at fat reduction and lean mass preservation. Metabolism 2024 · PMID 39481534
Dulaglutide safety basicsWho should avoid it, what to expect, what to watch
Avoid if
- Medullary thyroid cancer or MEN2, in you or a first-degree relative.
- Past pancreatitis, a trial exclusion for the once-weekly GLP-1 program.
- Insulin or sulfonylurea use without a plan for low blood sugar.
- Diabetic retinopathy, since fast glucose improvement can transiently worsen it.
- Gastroparesis or severe gut disease.
What’s expected
- Nausea, diarrhea, vomiting and reduced appetite, most often early.
- A small rise in resting heart rate.
- Weight loss with an Fc-fusion antibody fragment that gives a long half-life.
Watch for
- Constant upper belly pain boring through to the back, which can mean pancreatic inflammation.
- Right-sided pain with fever or yellow eyes, the gallbladder pattern.
- Sudden vision change in someone with diabetes.
Labs that tell you it’s working
- HbA1c: the primary efficacy readout across the dulaglutide trials.
- Lipase: an enzyme to check if abdominal pain develops.
- Cystatin C with eGFR: dehydration from vomiting can strain the kidney.
- Lipid Panel: weight loss usually improves triglycerides.
Long-acting GLP-1 receptor agonist fused to an Fc antibody fragment; anchored in a 4,949-person cardiovascular outcomes trial. PMID 31189511 PMID 34984808
Bloodwork to runHow you would know it is working: 9 tests in one order, code CAMERON
A panel picked from how it works and what it can move: the tests, and why each is on it.
Code CAMERON applies automatically. The before and after schedule and how to read the results are in the Skool lesson.
Dulaglutide FAQ4 common questions
- Is Dulaglutide approved for human use?
- Dulaglutide is an approved medicine for the uses on its label. This page covers research beyond those uses, as education, not medical advice.
- What is Dulaglutide researched for?
- Fat oxidation, appetite and energy regulation, insulin sensitivity and endurance capacity.
- Which labs show whether it's doing anything?
- HbA1c; Lipase; Cystatin C with eGFR; Lipid Panel: a baseline before you start and a recheck after. The panel on this page orders them in one cart.
- Where's the full protocol?
- In the Skool lesson for Dulaglutide: the protocol, dose and schedule, timing, what to stack, the cycle answer, the bloodwork plan and the cheat sheet. Protocol & dosing live there, not on the public site.



